Subretinal Hemorrhage and Exudative Maculopathy

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Subretinal Hemorrhage and Exudative Maculopathy trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 3

NCT04663750

Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to E…

The centre of the retina (macula) at the back of the eye contains cells that give us our central vision that we use for reading and recognising faces. These cel…

Germany210 participantsStarted 2021-04-16

Treatment: Pars plana vitrectomy, Intravitreal 2 mg aflibercept (Eylea, Bayer) will be injected at baseline then monthly for two further doses, then 2-monthly until month 12

All recent trials (2 shown)

UnknownPhase 2

NCT00161525

Pneumatic Displacement of Subretinal Hemorrhage With Perfluorocarbon Gases

Subretinal hemorrhage in the macula causes a significant loss of vision. This hemorrhage can be displaced by the use of a small volume of pure perfluorocarbon g…

United States25 participantsStarted 2003-10

Treatment: Pneumatic displacement